Pfizer has transferred its certain primarily off-patent branded and generic established medicines business (Upjohn Business) comprising of six brands which included Lyrica, Viagra, Celebrex, Amlogard, Daxid and Dilantin along with related business assets and liabilities to Mylan Pharmaceuticals, effective August 1, 2022. Accordingly, the Company has received the purchase consideration of Rs 180.48 crore from Mylan Pharmaceuticals. Earlier, the company had entered into a business transfer agreement (BTA) with Mylan Pharmaceuticals.
Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.
